Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31135475 | 1.00 | CYP19A1 (0.52) | CYP19A1ALDH1A1MAPTMAPK1PARP1 | |
| SCHEMBL9863135 | 0.89 | ALDH1A1 (0.56) | ALDH1A1MAPTTSHRL3MBTL1NPC1 | |
| SCHEMBL2007367 | 0.84 | TDP1 (0.53) | ALDH1A1MAPTPARP1KDM4EL3MBTL1 | |
| SCHEMBL6656568 | 0.83 | CYP19A1 (0.60) | CYP19A1ALDH1A1MAPTMAPK1PARP1 | |
| SCHEMBL6656564 | 0.83 | CYP19A1 (0.60) | CYP19A1ALDH1A1MAPTMAPK1PARP1 | |
| SCHEMBL4167297 | 0.83 | MAPT (0.51) | CYP19A1ALDH1A1MAPTMAPK1PARP1 | |
| SCHEMBL27374068 | 0.83 | ALDH1A1 (0.50) | ALDH1A1MAPTPARP1KDM4EL3MBTL1 | |
| SCHEMBL245137 | 0.82 | KDM4E (0.65) | ALDH1A1MAPK1KDM4ETSHRLMNA | |
| SCHEMBL29627840 | 0.82 | KDM4E (0.65) | ALDH1A1MAPK1KDM4ETSHRLMNA | |
| SCHEMBL1525400 | 0.82 | PARP1 (0.53) | ALDH1A1MAPK1PARP1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070874-A1 | BENZOYLFORMIC ACID AMIDE DERIVATIVE | KJ CHEMICALS CORPORATION (JP) | 2026-03-12 | — | — | US | disclosed |
| EP-4610249-A1 | BENZOYLFORMIC ACID AMIDE DERIVATIVE | KJ Chemicals Corporation (JP) | 2025-09-03 | — | — | EP | disclosed |
| WO-2018118838-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-9828350-B2 | 5,6-dihydro-2H-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-28 | — | — | US | disclosed |
| EP-2580200-B1 | 5,6-DIHYDRO-2H-[1,4]OXAZIN-3-YL-AMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-14 | — | — | EP | disclosed |
| US-20160152581-A1 | 5,6-DIHYDRO-2H-[1,4]OXAZIN-3-YL-AMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (US) | 2016-06-02 | — | — | US | disclosed |
| EP-2788335-B1 | 5-(3-AMINOPHENYL)-5-ALKYL-5,6-DIHYDRO-2H-[1,4]OXAZIN-3-AMINE DERIVATIVES FOR THE TREATMENT OF DISORDERS IN WHICH BETA-SECRETASE IS INVOLVED | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-13 | — | — | EP | disclosed |
| US-9193740-B2 | Bismacrocyclic compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193740-B2 | Bismacrocyclic compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-8951998-B2 | Quinoxaline-containing compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| WO-2009134987-A1 | DIFLUOROMETHYL-CONTAINING MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| US-20090274657-A1 | DIFLUOROMETHYL-CONTAINING MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090274657-A1 | DIFLUOROMETHYL-CONTAINING MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| EP-2078020-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2009-07-15 | — | — | EP | disclosed |
| WO-2009064975-A1 | QUINOXALINE-CONTAINING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20080261921-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261921-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261921-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| WO-2008124848-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008124848-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152581-A1 | 5,6-DIHYDRO-2H-[1,4]OXAZIN-3-YL-AMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | BACE2, BACE1, PSEN2 | CYP19A1 4420/4885ALDH1A1 3229/4885MAPT 34/4885 |
| US-20090274657-A1 | DIFLUOROMETHYL-CONTAINING MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | CTSC, DPP4, SPINT2 | CYP19A1 530/4885ALDH1A1 566/4885MAPT 4269/4885 |
| US-20080261921-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | MAP3K20, MAP3K19, MAP4K2 | CYP19A1 2626/4885ALDH1A1 4191/4885MAPT 2466/4885 |
| US-20260070874-A1 | BENZOYLFORMIC ACID AMIDE DERIVATIVE | CRYAA, BCAT1, BRCA1 | CYP19A1 579/4885ALDH1A1 88/4885MAPT 1426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.